Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.
The study will look at:
* How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
* The effects of bexobrutideg in the body when taken with these other treatments
* How well bexobrutideg treats CLL or SLL when taken with these other treatments
